Wilf-Miron Rachel, Bolotin Arkadi, Gordon Nesia, Porath Avi, Peled Ronit
Department of Health Systems Management, Faculty of Health Sciences, Ben Gurion University of the Negev, Beer Sheva, Israel.
BMC Endocr Disord. 2014 Dec 1;14:92. doi: 10.1186/1472-6823-14-92.
In primary health care systems where member's turnover is relatively low, the question, whether investment in quality of care improvement can make a business case, or is cost effective, has not been fully answered.The objectives of this study were: (1) to investigate the relationship between improvement in selected measures of diabetes (type 2) care and patients' health outcomes; and (2) to estimate the association between improvement in performance and direct medical costs.
A time series study with three quality indicators - Hemoglobin A1c (HbA1c) testing, HbA1C and LDL- cholesterol (LDL-C) control - which were analyzed in patients with diabetes, insured by a large health fund. Health outcomes measures used: hospitalization days, Emergency Department (ED) visits and mortality. Poisson, GEE and Cox regression models were employed. Covariates: age, gender and socio-economic rank.
96,553 adult (age >18) patients with diabetes were analyzed. The performance of the study indicators, significantly and steadily improved during the study period (2003-2009). Poor HbA1C (>9%) and inappropriate LDL-C control (>100 mg/dl) were significantly associated with number of hospitalization days. ED visits did not achieve statistical significance. Improvement in HbA1C control was associated with an annual average of 2% reduction in hospitalization days, leading to substantial reduction in tertiary costs. The Hazard ratio for mortality, associated with poor HbA1C and LDL-C, control was 1.78 and 1.17, respectively.
Our study demonstrates the effect of continuous improvement in quality care indicators, on health outcomes and resource utilization, among patients with diabetes. These findings support the business case for quality, especially in healthcare systems with relatively low enrollee turnover, where providers, in the long term, could "harvest" their investments in improving quality.
在成员更替率相对较低的初级卫生保健系统中,改善医疗质量的投资是否能产生商业效益或具有成本效益这一问题尚未得到充分解答。本研究的目的是:(1)调查2型糖尿病护理的选定指标改善与患者健康结果之间的关系;(2)估计绩效改善与直接医疗成本之间的关联。
一项时间序列研究,采用三个质量指标——糖化血红蛋白(HbA1c)检测、HbA1c和低密度脂蛋白胆固醇(LDL-C)控制——对由一家大型健康基金承保的糖尿病患者进行分析。使用的健康结果指标包括:住院天数、急诊就诊次数和死亡率。采用泊松、广义估计方程(GEE)和Cox回归模型。协变量包括:年龄、性别和社会经济等级。
对96553名成年(年龄>18岁)糖尿病患者进行了分析。在研究期间(2003 - 2009年),研究指标的绩效显著且稳步改善。HbA1c控制不佳(>9%)和LDL-C控制不当(>100 mg/dl)与住院天数显著相关。急诊就诊次数未达到统计学显著性。HbA1c控制的改善与住院天数平均每年减少2%相关,从而大幅降低了三级医疗成本。与HbA1c和LDL-C控制不佳相关的死亡率风险比分别为1.78和1.17。
我们的研究证明了持续改善质量护理指标对糖尿病患者的健康结果和资源利用的影响。这些发现支持了质量方面的商业案例,特别是在参保人员更替率相对较低的医疗系统中,从长期来看,医疗服务提供者可以“收获”他们在改善质量方面的投资。